Other diffuse gliomas, including IDH-mutant astrocytomas and oligodendrogliomas, follow a more protracted clinical course but remain incurable and ultimately progress to treatment-refractory disease. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).